Physicians' Academy for Cardiovascular Education

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

This lecture was part of a CME accredited symposium: SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? held at ESC 2016 in Rome

Video navigation menu

  • Multiple hypotheses on prevention of heart failure and reduction of mortality by SGLT-2 inhibitors 01:31
  • Direct or indirect effect on myocardium by SGLT-2 inhibitors 02:55
  • Lack of effect on myocardial infarction and absence of evidence for antiarrhythmic effect by SGLT-2 inhibitors 04:10
  • Blood pressure-lowering effect of SGLT-2 inhibitors 05:13
  • Renal effect of SGLT-2 inhibitors 11:40
  • Heart failure and mortality 12:54
  • Can we treat established heart failure with SGLT-2 inhibitors? 16:36

Educational information

Educational objectives of this symposium were to:

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Professor John McMurray: Professor of Medical Cardiology & Deputy - Director Institute of Cardiovascular & Medical Sciences - University of Glasgow, United Kingdom

Funding

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also see lecture - Challenging cardiovascular risk in diabetes: ready for a new approach by Prof. John Deanfield, MD, UCL, London Also see lecture - Overview of SGLT-2 inhibitors in T2DM management: current position & future promise by prof Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, USA